CLL IPI score can predict long term outcome for asymptomatic patient depending on their risk score low, intermediate or high there is a 30 % chance asymptomatic patients will never need treatment for CLL there are only phase 1 clinical trial available if patients are willing to participate in UK

FLAIR (Recruiting) Front-Line therapy in CLL: Assessment of Ibrutinib+ Rituximab   B029448 (Recruiting) A Multicenter, Double-Blond, Randomized, and Placebo-Controlled Phase IbStudy Evaluating the Safety of Adding Tocilizumab to Standard Premedications Prior to Administration of Obinutuzumab in Combination with Chlorambucil in Patients with Previously Untreated B-Cell Chronic Lymphocytic Leukemia and Comorbidities